Congressional investigation reveals ‘atypical,’ ‘inappropriate’ collaboration between FDA, Biogen

A report released by the House Energy and Commerce Committee paints a damning picture of the approval process for aducanumab, generically known as Aduhelm, the first Alzheimer’s drug made by Biogen Inc. and Eisai Inc.